
GSK promotes Jean Stephenne to chairman, biologicals
pharmafile | March 15, 2010 | Appointment | Research and Development, Sales and Marketing | GlaxoSmithKline, appointment, research and development, sales and marketing
GlaxoSmithKline has appointed Jean Stephenne chairman of GSK Biologicals, the company’s global vaccines division.
He is currently president and general manager of the unit, which is headquartered in Belgium.
The move is part of a succession plan for the vaccines business, which will see R&D chairman Dr Moncef Slaoui gradually assume operational responsibility for GSK Biologicals over the next two years.
GSK’s chief executive Andrew Witty said: “Succession planning is fundamental to GSK’s long-term success and today’s changes are clear evidence that we are taking proactive steps to maintain excellent leadership in our business.
“Jean has built a world-leading vaccines business and as chairman will continue to be instrumental in driving forward our public health agenda. Moncef has more than 17 years experience working in the vaccines area and has played a critical role in developing the strong pipeline we have today.
“These changes will ensure continued strong focus on delivery and development of this pipeline; they also reflect the more holistic approach we are taking to R&D capital investment.”
Related Content

PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025
The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …

AAX Biotech announces collaboration for cardiovascular antibody therapy
Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …

Research finds tablet effective in slowing progression of Alzheimer’s disease over 18 months
TauRx Pharmaceutics reports that hydromethylthionine mesylate (HMTM) could be an oral treatment for slowing the …






